Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205879630> ?p ?o ?g. }
- W4205879630 endingPage "1364.e2" @default.
- W4205879630 startingPage "1356" @default.
- W4205879630 abstract "Mast cells are key players in innate immunity and the TH2 adaptive immune response. The latter counterbalances the TH1 response, which is critical for antiviral immunity. Clonal mast cell activation disorders (cMCADs, such as mastocytosis and clonal mast cell activation syndrome) are characterized by abnormal mast cell accumulation and/or activation. No data on the antiviral immune response in patients with MCADs have been published.To study a comprehensive range of outcomes in patients with cMCAD with PCR- or serologically confirmed coronavirus disease 2019 and to characterize the specific anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune response in this setting.Clinical follow-up and outcome data were collected prospectively over a 12-month period by members of the French Centre de Référence des Mastocytoses rare disease network. Anti-SARS-CoV-2-specific T-cell activity was measured with an ELISA, and humoral responses were evaluated by assaying circulating levels of specific IgG, IgA, and neutralizing antibodies.Overall, 32 patients with cMCAD were evaluated. None required noninvasive or mechanical ventilation. Two patients were admitted to hospital for oxygen and steroid therapy. The SARS-CoV-2-specific immune response was characterized in 21 of the 32 patients. Most had high counts of circulating SARS-CoV-2-specific, IFN-γ-producing T cells and high titers of neutralizing antispike IgGs. The patients frequently showed spontaneous T-cell IFN-γ production in the absence of stimulation; this production was correlated with basal circulating tryptase levels (a marker of the mast cell burden).Patients with cMCADs might not be at risk of severe coronavirus disease 2019, perhaps due to their spontaneous production of IFN-γ." @default.
- W4205879630 created "2022-01-25" @default.
- W4205879630 creator A5001448942 @default.
- W4205879630 creator A5007732660 @default.
- W4205879630 creator A5010234667 @default.
- W4205879630 creator A5012892075 @default.
- W4205879630 creator A5014020914 @default.
- W4205879630 creator A5016193051 @default.
- W4205879630 creator A5024285608 @default.
- W4205879630 creator A5024987845 @default.
- W4205879630 creator A5030593310 @default.
- W4205879630 creator A5031269233 @default.
- W4205879630 creator A5032303743 @default.
- W4205879630 creator A5035150856 @default.
- W4205879630 creator A5035852992 @default.
- W4205879630 creator A5037307051 @default.
- W4205879630 creator A5040053640 @default.
- W4205879630 creator A5042618359 @default.
- W4205879630 creator A5044337764 @default.
- W4205879630 creator A5045287052 @default.
- W4205879630 creator A5047932130 @default.
- W4205879630 creator A5048736345 @default.
- W4205879630 creator A5049976253 @default.
- W4205879630 creator A5050913628 @default.
- W4205879630 creator A5052071966 @default.
- W4205879630 creator A5054154614 @default.
- W4205879630 creator A5055188307 @default.
- W4205879630 creator A5055664477 @default.
- W4205879630 creator A5055749187 @default.
- W4205879630 creator A5056713429 @default.
- W4205879630 creator A5060037546 @default.
- W4205879630 creator A5060713458 @default.
- W4205879630 creator A5061027575 @default.
- W4205879630 creator A5061207186 @default.
- W4205879630 creator A5061676018 @default.
- W4205879630 creator A5062185878 @default.
- W4205879630 creator A5062422990 @default.
- W4205879630 creator A5064820449 @default.
- W4205879630 creator A5064856085 @default.
- W4205879630 creator A5067808997 @default.
- W4205879630 creator A5069598264 @default.
- W4205879630 creator A5069694454 @default.
- W4205879630 creator A5072069761 @default.
- W4205879630 creator A5072225450 @default.
- W4205879630 creator A5075154206 @default.
- W4205879630 creator A5076773976 @default.
- W4205879630 creator A5076846925 @default.
- W4205879630 creator A5079658135 @default.
- W4205879630 creator A5082521577 @default.
- W4205879630 creator A5084326718 @default.
- W4205879630 creator A5090278193 @default.
- W4205879630 creator A5090616810 @default.
- W4205879630 creator A5091463936 @default.
- W4205879630 date "2022-05-01" @default.
- W4205879630 modified "2023-09-26" @default.
- W4205879630 title "Effective Anti–SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders" @default.
- W4205879630 cites W1531353407 @default.
- W4205879630 cites W1610686395 @default.
- W4205879630 cites W1964608118 @default.
- W4205879630 cites W1965551480 @default.
- W4205879630 cites W1988104022 @default.
- W4205879630 cites W2031686599 @default.
- W4205879630 cites W2034741339 @default.
- W4205879630 cites W2044960995 @default.
- W4205879630 cites W2054012164 @default.
- W4205879630 cites W2121216306 @default.
- W4205879630 cites W2565342730 @default.
- W4205879630 cites W2586672475 @default.
- W4205879630 cites W2819624235 @default.
- W4205879630 cites W2914596877 @default.
- W4205879630 cites W3009914955 @default.
- W4205879630 cites W3020654962 @default.
- W4205879630 cites W3025320502 @default.
- W4205879630 cites W3034858522 @default.
- W4205879630 cites W3041960835 @default.
- W4205879630 cites W3046194290 @default.
- W4205879630 cites W3047144258 @default.
- W4205879630 cites W3057728496 @default.
- W4205879630 cites W3088256443 @default.
- W4205879630 cites W3093472970 @default.
- W4205879630 cites W3130679622 @default.
- W4205879630 cites W3174019893 @default.
- W4205879630 doi "https://doi.org/10.1016/j.jaip.2021.12.038" @default.
- W4205879630 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35074600" @default.
- W4205879630 hasPublicationYear "2022" @default.
- W4205879630 type Work @default.
- W4205879630 citedByCount "1" @default.
- W4205879630 countsByYear W42058796302022 @default.
- W4205879630 crossrefType "journal-article" @default.
- W4205879630 hasAuthorship W4205879630A5001448942 @default.
- W4205879630 hasAuthorship W4205879630A5007732660 @default.
- W4205879630 hasAuthorship W4205879630A5010234667 @default.
- W4205879630 hasAuthorship W4205879630A5012892075 @default.
- W4205879630 hasAuthorship W4205879630A5014020914 @default.
- W4205879630 hasAuthorship W4205879630A5016193051 @default.
- W4205879630 hasAuthorship W4205879630A5024285608 @default.
- W4205879630 hasAuthorship W4205879630A5024987845 @default.
- W4205879630 hasAuthorship W4205879630A5030593310 @default.